Patents by Inventor Richard D. DiMarchi

Richard D. DiMarchi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
    Patent number: 9127088
    Abstract: Provided herein are glucagon superfamily peptides conjugated with NHR ligands that are capable of acting at a nuclear hormone receptor. Also provided herein are pharmaceutical compositions and kits of the conjugates of the invention. Further provided herein are methods of treating a disease, e.g., a metabolic disorder, such as diabetes and obesity, comprising administering the conjugates of the invention.
    Type: Grant
    Filed: May 10, 2011
    Date of Patent: September 8, 2015
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Richard D. DiMarchi, Bin Yang, Brian Finan
  • Ester-based insulin prodrugs
    Patent number: 9089539
    Abstract: Prodrug formulations of bioactive polypeptides are provided wherein the bioactive polypeptide has been modified by the linkage of a dipeptide to the bioactive polypeptide through an ester linkage. The prodrugs disclosed herein in some embodiments have extended half lives of at least 1.5 hours (e.g., at least 10 hours), and more typically greater than 20 hours and less than 70 hours, and are converted to the active form at physiological conditions through a non-enzymatic reaction driven by chemical instability.
    Type: Grant
    Filed: February 18, 2014
    Date of Patent: July 28, 2015
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Richard D. DiMarchi, Arnab De
  • Modified human plasma polypeptide or Fc scaffolds and their uses
    Patent number: 9074010
    Abstract: Modified human plasma polypeptides or Fc and uses thereof are provided.
    Type: Grant
    Filed: August 11, 2011
    Date of Patent: July 7, 2015
    Assignee: Ambrx, Inc.
    Inventors: Joseph Sheffer, Thea Norman, Richard D. Dimarchi, Anna-Maria A. Hays Putnam, Feng Tian, Stephanie Chu, Denise Krawitz, Ho Sung Cho
  • GIP-based mixed agonists for treatment of metabolic disorders and obesity
    Patent number: 9062124
    Abstract: Glucagon peptides that exhibit GIP agonist activity in addition to glucagon and/or GLP-I activity are provided. Pharmaceutical compositions comprising such glucagon peptides and therapeutic methods of using such peptides are also provided.
    Type: Grant
    Filed: June 16, 2009
    Date of Patent: June 23, 2015
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Richard D. Dimarchi, Tao Ma
  • SINGLE-CHAIN INSULIN AGONISTS EXHIBITING HIGH ACTIVITY AT THE INSULIN RECEPTOR
    Publication number: 20150148520
    Abstract: Single chain insulin analogs are provided having high potency and specificity for the insulin receptor. As disclosed herein optimally sized linking moieties can be used to link human insulin A and B chains, or analogs or derivatives thereof, wherein the carboxy terminus of the B25 amino acid of the B chain is linked to the amino terminus of the A1 amino acid of the A chain via the intervening linking moiety. In on embodiment the linking moiety comprises a polyethylene glycol of 6-16 monomer units and in an alternative embodiment the linking moiety comprises a non-native amino acid sequence derived form the IGF-1 C-peptide and comprising at least 8 amino acids and no more than 12 amino acid in length. Also disclosed are prodrug and conjugate derivatives of the single chain insulin analogs.
    Type: Application
    Filed: December 8, 2014
    Publication date: May 28, 2015
    Inventors: Richard D. DiMARCHI, Yulia AZRIEL, Zachary KAUR, Jonathan MEYERS, Todd PARODY, Yan ZHAO
  • GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS
    Publication number: 20150126440
    Abstract: Modified glucagon peptides are disclosed having enhanced potency at the glucagon receptor relative to native glucagon. Further modification of the glucagon peptides by forming lactam bridges or the substitution of the terminal carboxylic acid with an amide group produces peptides exhibiting glucagon/GLP-1 receptor co-agonist activity. The solubility and stability of these high potency glucagon analogs can be further improved by modification of the polypeptides by pegylation, substitution of carboxy terminal amino acids, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 26 (GPSSGAPPPS), SEQ ID NO: 27 (KRNRNNIA) and SEQ ID NO: 28 (KRNR).
    Type: Application
    Filed: November 7, 2014
    Publication date: May 7, 2015
    Inventors: Jonathan DAY, James PATTERSON, Joseph CHABENNE, Maria DiMARCHI, David L. SMILEY, Richard D. DiMARCHI
  • Glucagon analogs exhibiting physiological solubility and stability
    Patent number: 9018164
    Abstract: Modified glucagon peptides are disclosed having improved solubility and stability, wherein the native glucagon peptide has been modified by pegylation, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, or both.
    Type: Grant
    Filed: January 24, 2012
    Date of Patent: April 28, 2015
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Richard D. DiMarchi, David L. Smiley
  • Peptide compounds exhibiting glucagon antagonist and GLP-1 agonist activity
    Patent number: 8980830
    Abstract: Glucagon analogs are disclosed that exhibit both glucagon antagonist and GLP-1 agonist activity. In one embodiment, the glucagon antagonist/GLP-1 agonist comprises a modified amino acid sequence of native glucagon, in which the first one to five N-terminal amino acids of native glucagon is deleted and in which the alpha helix is stabilized.
    Type: Grant
    Filed: October 27, 2008
    Date of Patent: March 17, 2015
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Richard D. Dimarchi, Bin Yang, Chenguang Ouyang
  • Glucagon antagonists
    Patent number: 8981047
    Abstract: Glucagon antagonists are provided which comprise amino acid substitutions and/or chemical modifications to glucagon sequence. In one embodiment, the glucagon antagonists comprise a native glucagon peptide that has been modified by the deletion of the first two to five amino acid residues from the N-terminus and (i) an amino acid substitution at position 9 (according to the numbering of native glucagon) or (ii) substitution of the Phe at position 6 (according to the numbering of native glucagon) with phenyl lactic acid (PLA). In another embodiment, the glucagon antagonists comprise the structure A-B-C as described herein, wherein A is PLA, an oxy derivative thereof, or a peptide of 2-6 amino acids in which two consecutive amino acids of the peptide are linked via an ester or ether bond.
    Type: Grant
    Filed: October 23, 2008
    Date of Patent: March 17, 2015
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Richard D. Dimarchi, Bin Yang
  • Methods for treating metabolic disorders and obesity with a peptide comprising the amino acid sequence of SEQ ID No. 146
    Patent number: 8975223
    Abstract: Methods are provided for administering an extended half-life GLP-1/GIP coagonist peptide to a patient in need thereof for reducing weight gain, inducing weight loss, treating hyperglycemia, reducing blood glucose levels, or normalizing blood glucose levels in said patient.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: March 10, 2015
    Assignee: Marcadia Biotech, Inc.
    Inventors: Louis Vignati, Richard D. DiMarchi
  • Amide based glucagon and superfamily peptide prodrugs
    Patent number: 8969288
    Abstract: Prodrug formulations of glucagon superfamily peptides are provided wherein the glucagon superfamily peptide has been modified by the linkage of a dipeptide to the glucagon superfamily through an amide bond linkage. The prodrugs disclosed herein have extended half lives and are converted to the active form at physiological conditions through a non-enzymatic reaction driven by chemical instability.
    Type: Grant
    Filed: December 18, 2009
    Date of Patent: March 3, 2015
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Richard D. DiMarchi, Binbin Kou
  • Amide-based insulin prodrugs
    Patent number: 8946147
    Abstract: Prodrug formulations of insulin and insulin analogs are provided wherein the insulin peptide has been modified by an amide bond linkage of a dipeptide prodrug element. The prodrugs disclosed herein have extended half lives of at least 10 hours, and more typically greater than 2 hours, 20 hours and less than 70 hours, and are converted to the active form at physiological conditions through a non-enzymatic reaction driven by chemical instability.
    Type: Grant
    Filed: June 23, 2011
    Date of Patent: February 3, 2015
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Richard D. DiMarchi, Binbin Kou, Shujiang Cheng
  • Single-chain insulin agonists exhibiting high activity at the insulin receptor
    Patent number: 8940860
    Abstract: Single chain insulin analogs are provided having high potency and specificity for the insulin receptor. As disclosed herein optimally sized linking moieties can be used to link human insulin A and B chains, or analogs or derivatives thereof, wherein the carboxy terminus of the B25 amino acid of the B chain is linked to the amino terminus of the A1 amino acid of the A chain via the intervening linking moiety. In on embodiment the linking moiety comprises a polyethylene glycol of 6-16 monomer units and in an alternative embodiment the linking moiety comprises a non-native amino acid sequence derived form the IGF-1 C-peptide and comprising at least 8 amino acids and no more than 12 amino acid in length. Also disclosed are prodrug and conjugate derivatives of the single chain insulin analogs.
    Type: Grant
    Filed: June 16, 2011
    Date of Patent: January 27, 2015
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Richard D. DiMarchi, Julia Azriel, Zach Kaur, Jonathan Meyers, Todd Parody, Yan Zhao
  • Modified human four helical bundle polypeptides and their uses
    Patent number: 8906676
    Abstract: Modified human four helical bundle (4HB) polypeptides and uses thereof are provided.
    Type: Grant
    Filed: January 28, 2005
    Date of Patent: December 9, 2014
    Assignee: Ambrx, Inc.
    Inventors: Ho Sung Cho, Thomas O. Daniel, Richard D. DiMarchi, Anna-Maria Hays, Troy E. Wilson, Bee-Cheng Sim, David C. Litzinger
  • Modified human four helical bundle polypeptides and their uses
    Patent number: 8907064
    Abstract: Modified human four helical bundle (4HB) polypeptides and uses thereof are provided.
    Type: Grant
    Filed: October 18, 2007
    Date of Patent: December 9, 2014
    Assignee: Ambrx, Inc.
    Inventors: Ho Sung Cho, Thomas O. Daniel, Richard D. DiMarchi, Anna-Maria Hays, Troy E. Wilson, Bee-Cheng Sim, David C. Litzinger
  • Glucagon/GLP-1 receptor co-agonists
    Patent number: 8900593
    Abstract: Modified glucagon peptides are disclosed having enhanced potency at the glucagon receptor relative to native glucagon. Further modification of the glucagon peptides by forming lactam bridges or the substitution of the terminal carboxylic acid with an amide group produces peptides exhibiting glucagon/GLP-1 receptor co-agonist activity. The solubility and stability of these high potency glucagon analogs can be further improved by modification of the polypeptides by pegylation, substitution of carboxy terminal amino acids, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 26 (GPSSGAPPPS), SEQ ID NO: 27 (KRNRNNIA) and SEQ ID NO: 28 (KRNR).
    Type: Grant
    Filed: January 9, 2013
    Date of Patent: December 2, 2014
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Jonathan Day, James Patterson, Joseph Chabenne, Maria DiMarchi, David L. Smiley, Richard D. DiMarchi
  • Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
    Patent number: 8859491
    Abstract: Provided herein are glucagon superfamily peptides conjugated with GR ligands that are capable of acting at a glucocorticoid receptor. Also provided herein are pharmaceutical compositions and kits of the conjugates of the invention. Further provided herein are methods of treating a disease, e.g., a metabolic disorder, such as diabetes and obesity, comprising administering the conjugates of the invention.
    Type: Grant
    Filed: November 16, 2012
    Date of Patent: October 14, 2014
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Richard D. DiMarchi, Bin Yang
  • Modified Human Plasma Polypeptide or Fc Scaffolds and Their Uses
    Publication number: 20140296487
    Abstract: Modified human plasma polypeptides or Fc and uses thereof are provided.
    Type: Application
    Filed: November 22, 2013
    Publication date: October 2, 2014
    Applicant: AMBRX, INC.
    Inventors: Joseph SHEFFER, Thea NORMAN, Richard D. DIMARCHI, Anna-Maria A. HAYS PUTNAM, Feng TIAN, Stephanie CHU, Denise KRAWITZ, Ho Sung CHO
  • GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS
    Publication number: 20140221283
    Abstract: Provided herein are peptides and variant peptides that exhibit enhanced activity at the GLP-1 receptor, as compared to native glucagon.
    Type: Application
    Filed: June 12, 2012
    Publication date: August 7, 2014
    Applicant: Indiana University Research and Technology Corporation
    Inventors: Richard D. Dimarchi, David L. Smiley
  • ESTER-BASED INSULIN PRODRUGS
    Publication number: 20140212419
    Abstract: Prodrug formulations of bioactive polypeptides are provided wherein the bioactive polypeptide has been modified by the linkage of a dipeptide to the bioactive polypeptide through an ester linkage. The prodrugs disclosed herein in some embodiments have extended half lives of at least 1.5 hours (e.g., at least 10 hours), and more typically greater than 20 hours and less than 70 hours, and are converted to the active form at physiological conditions through a non-enzymatic reaction driven by chemical instability.
    Type: Application
    Filed: February 18, 2014
    Publication date: July 31, 2014
    Applicant: Indiana University Research and Technology Corporation
    Inventors: Richard D. DiMARCHI, Arnab DE